Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Elroy who wrote (75739)	6/6/2024 4:30:53 AM
From: Harshu Vyas	Respond to of 78673

RVNC - you've got me interested. Mark Foley, CEO, would have likely been the mentor of Taylor Harris of CUTR during their time together at Zeltiq. Just like Taylor, we have a dealmaker on our hands here - Previously, Mr. Foley was Chairman, President and CEO of ZELTIQ Aesthetics (ZLTQ). During his tenure, he led ZELTIQ’s growth from $68 million in annual revenue in 2012 to over $350 million in 2016, resulting in an appreciation of the Company’s stock of greater than tenfold and acquisition by Allergan (AGN) in April of 2017 for $2.5B. Mr. Foley has over 25 years of experience in the health care field... including U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic), where he was the founder and CEO. Also, he has partnered with a number of entrepreneurs to assist with the formation and capitalization of new health care companies while also serving as a Senior Advisor, Executive Chairman, interim CEO and board member to a number of medical device companies.